These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14605762)

  • 21. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
    Lu J; Celis E
    Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
    Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
    Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells.
    Matsuda K; Tsunoda T; Tanaka H; Umano Y; Tanimura H; Nukaya I; Takesako K; Yamaue H
    Cancer Immunol Immunother; 2004 Jul; 53(7):609-16. PubMed ID: 14735319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen.
    Huarte E; Sarobe P; Lasarte JJ; Brem G; Weiss EH; Prieto J; Borrás-Cuesta F
    Int J Cancer; 2002 Jan; 97(1):58-63. PubMed ID: 11774244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bridging Computational Vaccinology and Vaccine Development Through Systematic Identification, Characterization, and Downselection of Conserved and Variable Circumsporozoite Protein CD4 T Cell Epitopes From Diverse
    Noe AR; Terry FE; Schanen BC; Sassano E; Hindocha P; Phares TW; Moise L; Christen JM; Tucker KD; Kotraiah V; Drake DR; Martin WD; De Groot AS; Gutierrez GM
    Front Immunol; 2021; 12():689920. PubMed ID: 34168657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
    Marshall JL; Hoyer RJ; Toomey MA; Faraguna K; Chang P; Richmond E; Pedicano JE; Gehan E; Peck RA; Arlen P; Tsang KY; Schlom J
    J Clin Oncol; 2000 Dec; 18(23):3964-73. PubMed ID: 11099326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.
    Consogno G; Manici S; Facchinetti V; Bachi A; Hammer J; Conti-Fine BM; Rugarli C; Traversari C; Protti MP
    Blood; 2003 Feb; 101(3):1038-44. PubMed ID: 12393675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
    Alves PM; Viatte S; Fagerberg T; Michielin O; Bricard G; Bouzourene H; Vuilleumier H; Kruger T; Givel JC; Lévy F; Speiser DE; Cerottini JC; Romero P
    Cancer Immunol Immunother; 2007 Nov; 56(11):1795-805. PubMed ID: 17447064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
    Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY
    Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.
    Matsuzaki J; Qian F; Luescher I; Lele S; Ritter G; Shrikant PA; Gnjatic S; Old LJ; Odunsi K
    Cancer Immunol Immunother; 2008 Aug; 57(8):1185-95. PubMed ID: 18253733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
    Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
    Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient.
    Kobayashi H; Kokubo T; Takahashi M; Sato K; Miyokawa N; Kimura S; Kinouchi R; Katagiri M
    Immunogenetics; 1998 Apr; 47(5):398-403. PubMed ID: 9510558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients.
    Nagorsen D; Scheibenbogen C; Schaller G; Leigh B; Schmittel A; Letsch A; Thiel E; Keilholz U
    Int J Cancer; 2003 Jun; 105(2):221-5. PubMed ID: 12673683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
    Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
    Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic.
    Prickett SR; Voskamp AL; Phan T; Dacumos-Hill A; Mannering SI; Rolland JM; O'Hehir RE
    Clin Exp Allergy; 2013 Jun; 43(6):684-97. PubMed ID: 23711131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of mycobacterial peptide epitopes recognized by CD4+ T cells in association with multiple major histocompatibility complex class II molecules.
    Mustafa AS
    Nutrition; 1995; 11(5 Suppl):657-60. PubMed ID: 8748245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.